RxDoctor Payments Data

Gene Kim, MD

Dermatopathology · Los Angeles, CANPI 1144208182

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Philips North America LLC at 36.9% of the total. 2024 is the largest year on record at $97, 8.1 times the $12 reported in 2019. That places this record below the midpoint for dermatopathology clinicians in CA, where the typical reported total is $319.

$187in general payments, 2019–2025

Across 8 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$69
  • Johnson & Johnson$54
  • Novo Nordisk$36
  • Tempus AI, Inc$28

What the payments were for

  • Food & beverage$187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Philips North America LLC2$69
Johnson & Johnson(2 entities)3$54
Novo Nordisk2$36
Tempus AI, Inc1$28

How this compares

$187 in reported general payments places this provider in the 35th percentile of 76 dermatopathology providers in California.

See all dermatopathology providers in California

Medicare billing

Part B allowed, 2024
$1,045,060
Medicare patients
5,790
Services billed
11,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mycophenolate Mofetil31$3,894
Ketoconazole34$527
Fluocinonide13$398
Triamcinolone Acetonide21$202

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →